Document Detail

Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide.
MedLine Citation:
PMID:  18823738     Owner:  NLM     Status:  MEDLINE    
RNA-based therapeutic strategies are used widely due to their highly specific mode of action. However, the major obstacle in any RNA-based therapy is cellular delivery and stability in the cells. The self-assembly of the MS2 bacteriophage capsids has been used to develop virus-like particles (VLPs) for drug delivery. In this study, we utilized the heterobifunctional crosslinker, sulfosuccinimidyl-4-(p-maleimidophenyl)-butyrate (sulfo-SMPB), to conjugate the human immunodeficiency virus-1 (HIV-1) Tat peptide and MS2 VLPs; the antisense RNA against the 5'-untranslated region (UTR) and the internal ribosome entry site (IRES) of the hepatitis C virus (HCV) was packaged into these particles by using a two-plasmid coexpression system. The MS2 VLPs conjugated with the Tat peptide were then transferred into Huh-7 cells containing an HCV reporter system. The packaged antisense RNA showed an inhibitory effect on the translation of HCV. This paper describes our initial results with this system using the Tat peptide.
Baojun Wei; Yuxiang Wei; Kuo Zhang; Jing Wang; Ruihuan Xu; Sien Zhan; Guigao Lin; Wei Wang; Min Liu; Lunan Wang; Rui Zhang; Jinming Li
Related Documents :
17186478 - Similarity of rna secondary structures.
5940358 - Rna composition and base pairing.
18263618 - Solution structure of stem-loop alpha of the hepatitis b virus post-transcriptional reg...
2002508 - Involvement of "hinge" nucleotides of xenopus laevis 5 s rrna in the rna structural org...
6251898 - Solution studies on heme proteins. circular dichroism and optical rotation of glycera d...
7849698 - Variants of the heavy neurofilament subunit are associated with the development of amyo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-09-07
Journal Detail:
Title:  Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie     Volume:  63     ISSN:  1950-6007     ISO Abbreviation:  Biomed. Pharmacother.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-27     Completed Date:  2009-08-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8213295     Medline TA:  Biomed Pharmacother     Country:  France    
Other Details:
Languages:  eng     Pagination:  313-8     Citation Subset:  IM    
National Center for Clinical Laboratories, Beijing Hospital, Beijing, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Capsid Proteins / administration & dosage*,  genetics
Carcinoma, Hepatocellular / pathology
Cell Line, Tumor
Drug Delivery Systems
Gene Expression Regulation, Viral / drug effects
Genes, Reporter
Genetic Vectors / administration & dosage*,  genetics
Hepacivirus / genetics
Levivirus / ultrastructure*
Liver Neoplasms / pathology
Luciferases / biosynthesis,  genetics
Peptide Fragments / administration & dosage*
Protein Biosynthesis / drug effects
RNA, Antisense / administration & dosage*,  pharmacology
RNA, Small Interfering / administration & dosage*,  pharmacology
RNA, Viral / genetics
Recombinant Fusion Proteins / biosynthesis,  genetics
Reverse Transcriptase Polymerase Chain Reaction
Virus Internalization
tat Gene Products, Human Immunodeficiency Virus / administration & dosage*
Reg. No./Substance:
0/Capsid Proteins; 0/Peptide Fragments; 0/RNA, Antisense; 0/RNA, Small Interfering; 0/RNA, Viral; 0/Recombinant Fusion Proteins; 0/tat Gene Products, Human Immunodeficiency Virus; 0/tat peptide (47-57), Human immunodeficiency virus 1; EC 1.13.12.-/Luciferases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of biographical experience and bodily sensations in patients' adaptation to hypertension.
Next Document:  Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?